[ad_1]
The Swedish-British vaccine candidate Astra Zeneca has an efficiency of up to 70 percent on average today.
The vaccine, developed at Oxford, is comparatively cheap and easy to handle because it doesn’t need to be frozen, writes the BBC, calling the news a “triumph and disappointment.”
– It is just as you may have guessed, that we will see a sample map of vaccines that have different efficiencies and advantages and disadvantages. Each vaccine will find its niche of use, and in the end, you can combine it in different ways, says Matti Sällberg, a vaccine researcher at the Karolinska Institutet.
The United States Food and Drug Administration (FDA) has a 50 percent protection limit for an approval.
Countries talk about vaccinating this year
In another proven dosing method, Astra Zeneca’s vaccine shows 90 percent protection. Matti Sällberg believes that this part of the study will now be expanded.
Last week, Pfizer announced that its vaccine provides 95 percent protection in Phase 3 testing. Modern has also shown close to 95% protection.
The request for approval is sent centrally to the European Medicines Agency EMA. Now the authority must make its assessment, says Matti Sällberg.
– Now with this data, it is expected that everyone can start delivering their vaccines pending approval, we can only hope that it arrives just before or after the turn of the year.
The latest forecast from Sweden’s vaccine coordinator Richard Bergström is that Swedes will be able to start getting vaccinated in January.
See more:
Professor Matti Sällberg talks about when Swedes can start getting vaccinated.
